29.29
Precedente Chiudi:
$30.17
Aprire:
$29.5
Volume 24 ore:
200.73K
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.91B
Reddito:
$87.56M
Utile/perdita netta:
$-167.47M
Rapporto P/E:
-12.52
EPS:
-2.34
Flusso di cassa netto:
$-148.20M
1 W Prestazione:
-3.14%
1M Prestazione:
-4.56%
6M Prestazione:
-34.86%
1 anno Prestazione:
-14.43%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Confronta KYMR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KYMR
Kymera Therapeutics Inc
|
29.30 | 1.95B | 87.56M | -167.47M | -148.20M | -2.34 |
![]()
ONC
Beigene Ltd Adr
|
240.75 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
436.21 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.97 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.17 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-13 | Iniziato | Citigroup | Buy |
2024-12-10 | Iniziato | BTIG Research | Buy |
2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2024-11-18 | Iniziato | Stephens | Overweight |
2024-09-09 | Ripresa | Leerink Partners | Outperform |
2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2024-04-22 | Iniziato | Oppenheimer | Outperform |
2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-06-30 | Iniziato | Truist | Buy |
2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
2022-11-08 | Iniziato | Raymond James | Mkt Perform |
2022-08-15 | Iniziato | Jefferies | Buy |
2022-08-03 | Iniziato | Goldman | Buy |
2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
2022-04-28 | Iniziato | Credit Suisse | Outperform |
2022-03-10 | Iniziato | JP Morgan | Neutral |
2022-02-10 | Iniziato | Wells Fargo | Overweight |
2021-09-30 | Iniziato | B. Riley Securities | Neutral |
2021-09-30 | Iniziato | Stifel | Buy |
2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
2021-05-21 | Iniziato | UBS | Buy |
2021-04-14 | Iniziato | Berenberg | Buy |
2020-12-04 | Iniziato | H.C. Wainwright | Buy |
2020-09-15 | Iniziato | BofA Securities | Neutral |
2020-09-15 | Iniziato | Cowen | Outperform |
2020-09-15 | Iniziato | Guggenheim | Buy |
2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times
Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com
Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria
Kymera Therapeutics presents preclinical data for KT-621 - TipRanks
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus
Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan
Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com
Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus
UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st
When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga
Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus
Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus
Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus
Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK
Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech
B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com
BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Kymera advances oral drug for autoimmune diseases - Investing.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus
Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks
Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus
Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus
Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus
Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa
Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada
Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research
Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):